RA
RAFA.US Rafarma Pharmaceuticals Inc
- Market cap
- USD 702K
- P/E
- -
- P/B
- -
- ROE
- 3.4%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is RAFA.US undervalued?
Graham numberThe Graham number of Rafarma Pharmaceuticals Inc cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Rafarma Pharmaceuticals Inc fundamental analysis
No fundamental analysis for Rafarma Pharmaceuticals Inc yet.
Rafarma Pharmaceuticals Inc stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Rafarma Pharmaceuticals Inc
Rafarma Pharmaceuticals, Inc. engages in the development and production of medical equipment. It is also involved in the supply of equipment for hospitals and clinics. Rafarma Pharmaceuticals, Inc. was formerly known as Johnston Acquisition Corp. and changed its name to Rafarma Pharmaceuticals, Inc. in October 2012. The company was incorporated in 1982 and is based in Draper, Utah. As of October 19, 2020, Rafarma Pharmaceuticals, Inc. operates as a subsidiary of R. & D. Bioc…
Full company profileRafarma Pharmaceuticals Inc financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Rafarma Pharmaceuticals Inc annual financial statements
| Item | 2014 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | - | 125K | 147K | 11.4M | 74.7M | 77.4M | 64.3M | 10.1M | 9.08M | 9.18M | 1.34M |
| Gross Profit | - | -70.8K | 3.61K | 3.36M | 33.1M | 27.3M | 22.8M | 600K | 674K | 761K | 575K |
| Operating Income | -1.00K | -97.1K | -5.58K | 3.09M | 19.1M | 14.7M | 7.15M | 313K | 405K | 489K | 397K |
| EBITDA | -1.00K | -97.1K | -5.58K | 3.56M | 18.8M | 14.7M | 6.45M | 527K | 342K | 489K | 397K |
| Net Income | -14.8K | -97.1K | -6.18K | 3.05M | 14.8M | 11.6M | 4.96M | 273K | 266K | 349K | 356K |
| EPS | 0.00 | 0.00 | 0.00 | 0.03 | 0.17 | 0.13 | 0.06 | 0.00 | 0.00 | 0.00 | 0.00 |
| Balance Sheet | |||||||||||
| Total Assets | 460M | 6.31M | 6.34M | 20.5M | 70.6M | 89.3M | 98.3M | 12.2M | 12.0M | 12.0M | 12.1M |
| Total Liabilities | 284K | 304K | 319K | 11.4M | 18.5M | 19.8M | 20.4M | 1.65M | 1.65M | 1.49M | 1.61M |
| Shareholders' Equity | 460M | 6.00M | 6.02M | 9.13M | 52.1M | 69.5M | 77.9M | 10.5M | 10.4M | 10.5M | 10.5M |
| Cash & Short-term Investments | - | 1.51K | 12.3K | 1.43M | 6.12M | 13.6M | 18.8M | 66.0K | 77.0K | 58.0K | 63.0K |
| Total Debt | 178K | 178K | 178K | 162K | 496K | 1.70M | 909K | - | - | 23.0K | 21.0K |
| Cash Flow | |||||||||||
| Operating Cash Flow | -1.00K | 106K | -75.4K | 10.2M | -8.76M | 2.88M | 18.8M | -50.7M | 44.0K | 112K | 60.0K |
| Capital Expenditure | 0.00 | 2.69K | 0.00 | 11.3M | 0.00 | 0.00 | 12.1M | 50.7M | 44.0K | 128K | 2.67K |
| Free Cash Flow | -1.00K | 103K | -75.4K | -1.09M | -8.76M | 2.88M | 6.69M | -50.7M | 44.0K | -16.0K | 57.3K |
| Ratios | |||||||||||
| ROE | 0.0% | -1.6% | -0.1% | 33.4% | 28.5% | 16.7% | 6.4% | 2.6% | 2.6% | 3.3% | 3.4% |
| ROA | 0.0% | -1.5% | -0.1% | 14.9% | 21.0% | 13.0% | 5.0% | 2.2% | 2.2% | 2.9% | 2.9% |
| Net Profit Margin | - | -77.6% | -4.2% | 26.7% | 19.9% | 15.0% | 7.7% | 2.7% | 2.9% | 3.8% | 26.5% |
| Debt to Equity | 0.00x | 0.03x | 0.03x | 0.02x | 0.01x | 0.02x | 0.01x | - | - | 0.00x | 0.00x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Rafarma Pharmaceuticals Inc dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | USD 3.42M | 0.04 | 29.6% |
| 2020 | USD 5.15M | 0.06 | 34.7% |
| 2019 | - | - | - |
| 2018 | - | - | - |
| 2017 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 1:10 on Dec 5, 2012.
Who owns Rafarma Pharmaceuticals Inc
Ownership data of Rafarma Pharmaceuticals Inc is not available yet.
Rafarma Pharmaceuticals Inc company profile
- Company name
- Rafarma Pharmaceuticals Inc
- Ticker
- RAFA.US
- Exchange
- USA Stocks
- Sector
- Healthcare
- Industry
- Pharmaceuticals
- Fiscal year end
- December
- Address
- 12465 South Fort St, Draper, UT, United States, 84020
- Phone
- 307 429 2029
- Website
- rafarma.co
About Rafarma Pharmaceuticals Inc
Rafarma Pharmaceuticals, Inc. engages in the development and production of medical equipment. It is also involved in the supply of equipment for hospitals and clinics. Rafarma Pharmaceuticals, Inc. was formerly known as Johnston Acquisition Corp. and changed its name to Rafarma Pharmaceuticals, Inc. in October 2012. The company was incorporated in 1982 and is based in Draper, Utah. As of October 19, 2020, Rafarma Pharmaceuticals, Inc. operates as a subsidiary of R. & D. Biocogency Laboratories Inc. Ltd.
Rafarma Pharmaceuticals Inc management
3- Mr. Sergey Brusnitsin J.D., Ph.D.Chief Financial Officer and Director
- Mr. Anucha PhetphengExecutive Vice-President for Thai Operations · born 1965
- Mr. Alexander Ageev Esq.Secretary, Treasurer and Director